PHARMACEUTICAL FORMULATIONS OF A BRUTON'S TYROSINE KINASE INHIBITOR
First Claim
Patent Images
1. A solid tablet formulation comprising ibrutinib and pharmaceutically acceptable excipients, wherein the ibrutinib is a compound with the structure of Compound 1,
1 Assignment
0 Petitions
Accused Products
Abstract
Described herein are pharmaceutical formulations of Bruton'"'"'s tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one. Also disclosed are methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
11 Citations
25 Claims
- 1. A solid tablet formulation comprising ibrutinib and pharmaceutically acceptable excipients, wherein the ibrutinib is a compound with the structure of Compound 1,
- 10. A solid tablet formulation comprising ibrutinib and pharmaceutically acceptable excipients, wherein the ibrutinib is a compound with the structure of Compound 1,
- 24. A solid tablet formulation comprising ibrutinib and pharmaceutically acceptable excipients, wherein ibrutinib is a compound with the structure of Compound 1,
Specification